Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
Titel:
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
Auteur:
Yang, James Chih-Hsin Wu, Yi-Long Schuler, Martin Sebastian, Martin Popat, Sanjay Yamamoto, Nobuyuki Zhou, Caicun Hu, Cheng-Ping O'Byrne, Kenneth Feng, Jifeng Lu, Shun Huang, Yunchao Geater, Sarayut L Lee, Kye Young Tsai, Chun-Ming Gorbunova, Vera Hirsh, Vera Bennouna, Jaafar Orlov, Sergey Mok, Tony Boyer, Michael Su, Wu-Chou Lee, Ki Hyeong Kato, Terufumi Massey, Dan Shahidi, Mehdi Zazulina, Victoria Sequist, Lecia V